Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

ARS Pharmaceuticals, Inc. (SPRY) had Revenue of $15.72M for the most recently reported fiscal quarter, ending 2025-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-06-30

Income Statement Financials
Revenue	$15.72M
Net Income	$-44.88M
Cost of Goods Sold	$4.98M
Gross Profit	$10.73M
Operating Expenses	$63.33M
Operating Income	$-47.61M
Non-Operating Income/Expense	$2.73M
Pre-Tax Income	$-44.88M
Normalized Pre-Tax Income	$-44.88M
Income after Taxes	$-44.88M
Income from Continuous Operations	$-44.88M
Consolidated Net Income/Loss	$-44.88M
Normalized Income after Taxes	$-44.88M
EBIT	$-47.61M
EBITDA	$-48.80M
Weighted-Average Shares Outstanding (Basic)	98.36M
Weighted-Average Shares Outstanding (Diluted)	98.36M
Earnings per Share (EPS) (Basic)	$-0.46
Earnings per Share (EPS) (Diluted)	$-0.46
Balance Sheet Financials
Current Assets	$281.44M
Property, Plant, and Equipment	$1.07M
Long-Term Assets	$32.04M
Total Assets	$313.47M
Current Liabilities	$45.60M
Long-Term Debt	$71.96M
Long-Term Liabilities	$75.55M
Total Liabilities	$121.15M
Common Equity	$192.32M
Tangible Shareholders Equity	$179.35M
Shareholders Equity	$192.32M
Common Shares Outstanding	98.70M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-80.33M
Cash Flow from Investing Activities	$77.64M
Cash Flow from Financial Activities	$3.42M
Beginning Cash	$50.82M
End Cash	$51.54M
Increase/Decrease in Cash	$0.72M
Stock-Based Compensation	$10.67M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	6.17
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.27
Debt to Equity Ratio	0.37
Gross Margin	68.29%
Operating Margin	-302.95%
EBIT Margin	-302.95%
EBITDA Margin	--
Pre-Tax Profit Margin	-285.57%
Profit Margin	-285.57%
Free Cash Flow	$-80.48M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.05
Inventory Turnover	0.57
Receiveable Turnover	0.63
Days Sales in Receivables	143.88
Return on Equity	-23.34%
Return on Tangible Equity	-25.03%
Return on Assets	-14.32%
Return on Investments	-16.98%
Book Value Per Share	$1.95
Free Cash Flow per Share	$-0.82
Operating Cash Flow per Share	$-0.82

Data from Zacks Investment Research, Inc.